Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Y Zhang, Changli Qian, Erica M. Holdridge, Guruprasad Ananda, Tao Jiang, Jing Ni, Shaozhen Xie, Hao Gu, Renlei Ji, Elena V. Ivanova, Marisa R. Nucci, Zhe Wang, Kaifu Chen, Bose S. Kochupurakkal, , Jean J. Zhao
This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.
Nature Communications · May 4, 2026Peer-reviewedCancer Biology